Literature DB >> 6223011

Autoradiographical demonstration of C3b receptor activity on resident peritoneal macrophages.

R de Water, L A Ginsel, W T Daems, M R Daha.   

Abstract

The present study was performed to evaluate the usefulness of 125I-labelled C3b bound to constituents of sheep erythrocyte membranes (125I-C3b-OR) for the demonstration of C3b receptor activity of resident peritoneal macrophages at the electron-microscopical level. The binding of 125I-C3b-OR to the cells was studied in biochemical and autoradiographical experiments. The amount of cell-associated radioactivity was dependent on the presence of unlabelled aggregated C3b (AC3b) in a dose-response manner, and diminished strongly after functional inactivation of the receptor by trypsin treatment. In addition, it was found that at 4 degrees C most of the label was associated with the cell surface. However, when the incubation temperature was raised from 4 degrees C to 37 degrees C, internalization of the label was observed. These results indicate that 125I-C3b-OR is a suitable agent for further characterization of the C3b receptor-function of resident peritoneal macrophages at the electron-microscopical level.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6223011     DOI: 10.1007/bf00490891

Source DB:  PubMed          Journal:  Histochemistry        ISSN: 0301-5564


  26 in total

Review 1.  Endocytosis.

Authors:  S C Silverstein; R M Steinman; Z A Cohn
Journal:  Annu Rev Biochem       Date:  1977       Impact factor: 23.643

2.  Role of binding through C3b and IgG in polymorphonuclear neutrophil function: studies with trypsin-generated C3b.

Authors:  S L Newman; R B Johnston
Journal:  J Immunol       Date:  1979-10       Impact factor: 5.422

3.  Assay of membrane complement receptors (CR1 and CR2) with C3b- and C3d-coated fluorescent microspheres.

Authors:  J D Lambris; G D Ross
Journal:  J Immunol       Date:  1982-01       Impact factor: 5.422

4.  Enhanced alternative complement pathway-dependent degradation of soluble immunoglobulin aggregates by macrophages.

Authors:  M R Daha; L A Van Es
Journal:  Immunology       Date:  1981-07       Impact factor: 7.397

5.  Augmentation of macrophage complement receptor function in vitro. II. Characterization of the effects of a unique lymphokine upon the phagocytic capabilities of macrophages.

Authors:  F M Griffin; J A Griffin
Journal:  J Immunol       Date:  1980-08       Impact factor: 5.422

6.  Enhanced degradation of soluble immunoglobulin aggregates by macrophages in the presence of complement.

Authors:  A Kijlstra; L A Van Es; M R Daha
Journal:  Immunology       Date:  1979-07       Impact factor: 7.397

7.  Heterogeneity of concanavalin A binding by mouse peritoneal macrophages.

Authors:  R de Water; C A van Blitterswijk; W T Daems; L A Ginsel
Journal:  Histochemistry       Date:  1982

8.  Membrane distribution and adsorptive endocytosis by C3b receptors on human polymorphonuclear leukocytes.

Authors:  D T Fearon; I Kaneko; G G Thomson
Journal:  J Exp Med       Date:  1981-06-01       Impact factor: 14.307

9.  Studies of the macrophage complement receptor. Alteration of receptor function upon macrophage activation.

Authors:  C Bianco; F M Griffin; S C Silverstein
Journal:  J Exp Med       Date:  1975-06-01       Impact factor: 14.307

10.  Receptors for complement of leukocytes.

Authors:  W H Lay; V Nussenzweig
Journal:  J Exp Med       Date:  1968-11-01       Impact factor: 14.307

View more
  2 in total

1.  Expression of the atrial natriuretic peptide gene in the cardiac muscle of rat extrapulmonary and intrapulmonary veins.

Authors:  D R Springall; M Bhatnagar; J Wharton; Q Hamid; S Gulbenkian; M Hedges; L Meleagros; S R Bloom; J M Polak
Journal:  Thorax       Date:  1988-01       Impact factor: 9.139

2.  Degradation of aggregates of activated C3 (C3b) by monocytes of patients with rheumatoid arthritis is related to vasculitis.

Authors:  A H Heurkens; F C Breedveld; C V Keur; R Brand; M R Daha
Journal:  Clin Exp Immunol       Date:  1990-05       Impact factor: 4.330

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.